TRXADE HEALTH INC (MEDS) Forecast, Price Target & Analyst Ratings
NASDAQ:MEDS • US89846A4058
7.59 USD
+0.35 (+4.83%)
At close: Sep 20, 2024
7.591 USD
+0 (+0.01%)
After Hours: 9/20/2024, 8:07:08 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TRXADE HEALTH INC (MEDS).
Forecast Snapshot
Consensus Price Target
$6.89
-9.29% Downside
Next Earnings Forecast
Release DateN/A
PeriodQ3 / 2024
EPS Estimate-$0.15
Revenue Estimate2.525M
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$6.89
Upside
-9.29%
From current price of $7.59 to mean target of $6.89, Based on 7 analyst forecasts
Low
$6.82
Median
$6.89
High
$7.09
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 analysts have analysed MEDS and the average price target is 6.89 USD. This implies a price decrease of -9.29% is expected in the next year compared to the current price of 7.59.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
MEDS was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about MEDS.
In the previous month the buy percentage consensus was at a similar level.
MEDS was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-05-16 | EF Hutton | Maintains | Buy -> Buy |
| 2023-03-28 | Maxim Group | Maintains | Buy |
| 2021-12-09 | EF Hutton | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ3 / 2024
EPS Estimate-$0.15
Revenue Estimate2.525M
Revenue Q2Q22.69%
EPS Q2Q0.00%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|
| Revenue YoY % growth | 9.89M -42.23% | 11.45M 15.77% | 8.272M -27.75% | 9.486M 14.67% | |
| EBITDA YoY % growth | -4.05M -128.81% | -2.74M 32.35% | -6.429M -134.64% | -663K 89.69% | |
| EBIT YoY % growth | -4.06M -128.09% | -2.75M 32.27% | -7.263M -164.12% | -887.4K 87.78% | |
| Operating Margin | -41.05% | -24.02% | -87.80% | -9.35% | |
| EPS YoY % growth | -1.91 -730.43% | -4.80 -151.31% | N/A 77.69% | -0.46 57.14% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 24 | Q4 / 24 | |
|---|---|---|
| EPS Q2Q % growth | -0.15 | 0.00 100.00% |
| Revenue Q2Q % growth | 2.525M 22.69% | 2.591M 10.14% |
| EBITDA Q2Q % growth | -137.7K 73.04% | -40.8K 99.24% |
| EBIT Q2Q % growth | -193.8K 77.07% | -96.9K 98.44% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
TRXADE HEALTH INC / MEDS Forecast FAQ
What do analysts expect the price target to be for TRXADE HEALTH INC (MEDS)?
7 analysts have analysed MEDS and the average price target is 6.89 USD. This implies a price decrease of -9.29% is expected in the next year compared to the current price of 7.59.
What are the consensus estimates for MEDS stock next earnings?
The consensus EPS estimate for the next earnings of TRXADE HEALTH INC (MEDS) is -0.15 USD and the consensus revenue estimate is 2.52M USD.
How many analysts have analysed TRXADE HEALTH INC (MEDS)?
The number of analysts covering TRXADE HEALTH INC (MEDS) is 7.